Valeant Builds Outside Of Dermatology With Bausch + Lomb Buy
This article was originally published in The Rose Sheet
Acquisition of Bausch + Lomb for $8.7 billion vaults Valeant Pharmaceuticals into consumer eye care and positions the firm to compete against pharma giants. Analysts see the move as representing “a good fit,” and the acquisition is not likely to be the last for Valeant, which has made M&A an integral part of its strategy.
You may also be interested in...
J&J takes same approach GSK, Pfizer, Merck & Co, Merck and Novartis have with their consumer health businesses, Bausch Health is starting and Sanofi says it will.
FDA invites public input in preparation for the seventh meeting of national authorities under the International Cooperation on Cosmetics Regulation, while The National Toxicology Program requests information on technologies and non-animal approaches that can be used to screen compounds for potential neurotoxicity. More news in brief.
The addition of AcneFree to Valeant Pharma’s OTC portfolio will complement the Montreal firm’s CeraVe skin hydration line and augment its shelf space in U.S. retail doors. Valeant announced $64 million purchase from University Medical earlier this month.